PMGC Holdings Inc. (NASDAQ:ELAB) Sees Significant Decline in Short Interest

PMGC Holdings Inc. (NASDAQ:ELAB) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 38,846 shares, a decline of 31.4% from the November 30th total of 56,663 shares. Currently, 5.7% of the company’s shares are sold short. Based on an average daily volume of 442,173 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 442,173 shares, the short-interest ratio is currently 0.1 days. Currently, 5.7% of the company’s shares are sold short.

PMGC Trading Down 5.9%

NASDAQ ELAB traded down $0.09 on Monday, hitting $1.46. 128,693 shares of the company were exchanged, compared to its average volume of 486,408. The company has a market cap of $992,120.00, a PE ratio of -0.09 and a beta of 0.28. The stock has a fifty day moving average of $4.74 and a 200-day moving average of $6.00. PMGC has a 12 month low of $1.45 and a 12 month high of $99.72.

PMGC (NASDAQ:ELAB) last announced its quarterly earnings data on Friday, November 14th. The company reported ($4.95) earnings per share for the quarter. The firm had revenue of $0.29 million for the quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (e)” rating on shares of PMGC in a research note on Monday, December 15th. Wall Street Zen upgraded PMGC to a “sell” rating in a report on Saturday, October 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, PMGC has a consensus rating of “Sell”.

PMGC Company Profile

Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021. Elevai Labs, Inc was incorporated in 2020 and is based in Newport Beach, California.